Aucta maintains a vertically integrated global manufacturing network, combining FDA- and NMPA-approved facilities in Shanghai and New Jersey. The   Lingang facility serves as the primary large-scale production and global supply hub, capable of producing oral powders, tablets, capsules, suspensions, and softgel under both Chinese and U.S. cGMP standards. The  New Jersey site specializes in high-value dosage forms such as nasal sprays, oral suspensions, and dry powders, supporting both commercial and orphan drug production.

The company’s centralized Quality Management System (QMS) ensures consistent standards, validated analytical methods, and full traceability across all sites. This integrated infrastructure allows Aucta a guaranteed global supply reliability, and maintained a product quality — a key competitive advantage underpinning its ability to deliver complex formulations worldwide.